Cryotherapeutics: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Cryotherapeutics
Largest movements
- Current investments -€2.8m
down €2.8m (-65.1%), from €4.3m to €1.5m
- Cash -€396,645
down €396,645 (-12.5%), from €3.2m to €2.8m
mainly Investment in fixed assets (net) (-€2.9m) and Net result for the year (-€2.3m)
- Profit (loss) carried forward -€2.3m
down €2.3m (-25.7%), from -€8.8m to -€11.0m
- Other debts -€563,702
down €563,702 (-86.6%), from €651,056 to €87,354
- Depreciation +€136,199
up €136,199 (+5.2%), from €2.6m to €2.7m
- Staff costs +€101,251
up €101,251 (+10.1%), from €1.0m to €1.1m
- Gross operating margin -€53,058
down €53,058, from €23,850 to -€29,208
- Taxes +€39,472
up €39,472 (+32.2%), from -€122,744 to -€83,272
- Financial income +€20,444
up €20,444 (+1.3%), from €1.5m to €1.5m
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €24,760,933 | €21,780,861 | -€3.0m | -12.0% |
| Fixed assets | 21/28 | €16,631,021 | €16,743,735 | +€112,715 | +0.7% |
| Tangible fixed assets | 22/27 | €21,021 | €133,735 | +€112,715 | +536% |
| Furniture and vehicles | 24 | €21,021 | €38,893 | +€17,872 | +85.0% |
| Other tangible fixed assets | 26 | - | €94,843 | +€94,843 | |
| Financial fixed assets | 28 | €16,610,000 | €16,610,000 | = | 0.0% |
| Current assets | 29/58 | €8,129,912 | €5,037,126 | -€3.1m | -38.0% |
| Amounts receivable after more than one year | 29 | €513,621 | €560,492 | +€46,870 | +9.1% |
| Other amounts receivable | 291 | €513,621 | €560,492 | +€46,870 | +9.1% |
| Amounts receivable within one year | 40/41 | €91,961 | €131,047 | +€39,086 | +42.5% |
| Other amounts receivable | 41 | €91,961 | €131,047 | +€39,086 | +42.5% |
| Current investments | 50/53 | €4,300,000 | €1,500,000 | -€2.8m | -65.1% |
| Cash at bank and in hand | 54/58 | €3,180,816 | €2,784,170 | -€396,645 | -12.5% |
| Deferred charges and accrued income | 490/1 | €43,514 | €61,417 | +€17,903 | +41.1% |
| Total equity and liabilities | 10/49 | €24,760,933 | €21,780,861 | -€3.0m | -12.0% |
| Equity | 10/15 | €23,345,446 | €21,087,147 | -€2.3m | -9.7% |
| Contributions | 10/11 | €32,119,263 | €32,119,263 | = | 0.0% |
| Capital | 10 | €32,119,263 | €32,119,263 | = | 0.0% |
| Issued capital | 100 | €32,119,263 | €32,119,263 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€8,773,817 | -€11,032,116 | -€2.3m | -25.7% |
| Amounts payable | 17/49 | €1,415,487 | €693,714 | -€721,773 | -51.0% |
| Amounts payable within one year | 42/48 | €1,412,650 | €692,921 | -€719,729 | -50.9% |
| Trade debts | 44 | €529,518 | €424,327 | -€105,190 | -19.9% |
| Suppliers | 440/4 | €529,518 | €424,327 | -€105,190 | -19.9% |
| Taxes, remuneration and social security | 45 | €232,077 | €181,240 | -€50,837 | -21.9% |
| Taxes | 450/3 | €48,892 | €37,366 | -€11,526 | -23.6% |
| Remuneration and social security | 454/9 | €183,185 | €143,873 | -€39,312 | -21.5% |
| Other amounts payable | 47/48 | €651,056 | €87,354 | -€563,702 | -86.6% |
| Accrued charges and deferred income | 492/3 | €2,836 | €793 | -€2,043 | -72.0% |
| Remuneration, social security and pensions | 62 | €1,000,496 | €1,101,747 | +€101,251 | +10.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,603,217 | €2,739,416 | +€136,199 | +5.2% |
| Other operating charges | 640/8 | €4,014 | €1,464 | -€2,550 | -63.5% |
| Non-recurring operating charges | 66A | €18,799 | - | -€18,799 | |
| Gross operating margin | 9900 | €23,850 | -€29,208 | -€53,058 | |
| Operating profit (loss) | 9901 | -€3,602,676 | -€3,871,836 | -€269,159 | -7.5% |
| Financial income | 75/76B | €1,526,319 | €1,546,763 | +€20,444 | +1.3% |
| Recurring financial income | 75 | €1,526,319 | €1,546,763 | +€20,444 | +1.3% |
| Financial charges | 65/66B | €17,745 | €16,497 | -€1,248 | -7.0% |
| Recurring financial charges | 65 | €17,745 | €16,497 | -€1,248 | -7.0% |
| Profit (loss) for the period before taxes | 9903 | -€2,094,103 | -€2,341,570 | -€247,467 | -11.8% |
| Income taxes | 67/77 | -€122,744 | -€83,272 | +€39,472 | +32.2% |
| Profit (loss) for the period | 9904 | -€1,971,359 | -€2,258,299 | -€286,939 | -14.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,971,359 | -€2,258,299 | -€286,939 | -14.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 24 October 2026 via checked.be.